期刊
JOURNAL OF MOLECULAR ENDOCRINOLOGY
卷 48, 期 1, 页码 R1-R12出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/JME-11-0121
关键词
-
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Universite Denis Diderot-Paris 7
- Assistance Publique - Hopitaux de Paris (AP-HP)
- Association pour la Recherche sur le Cancer (ARC)
- Federation pour la Recherche sur le Cerveau (FRC)
- Medical Research Council (UK)
The neuropeptide somatostatin (SRIF) is an important modulator of neurotransmission in the central nervous system and acts as a potent inhibitor of hormone and exocrine secretion. In addition, SRIF regulates cell proliferation in normal and tumorous tissues. The six somatostatin receptor subtypes (sst1, sst2A, sst2B, sst3, sst4, and sst5), which belong to the G protein-coupled receptor (GPCR) family, share a common molecular topology: a hydrophobic core of seven transmembrane-spanning a-helices, three intracellular loops, three extracellular loops, an amino-terminus outside the cell, and a carboxyl-terminus inside the cell. For most of the GPCRs, intracytosolic sequences, and more particularly the C-terminus, are believed to interact with proteins that are mandatory for either exporting neosynthesized receptor, anchoring receptor at the plasma membrane, internalization, recycling, or degradation after ligand binding. Accordingly, most of the SRIF receptors can traffic not only in vitro within different cell types but also in vivo. A picture of the pathways and proteins involved in these processes is beginning to emerge. Journal of Molecular Endocrinology (2012) 48, R1-R12
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据